Clinical Trials Related to Nab-paclitaxel

Related studies linked through entity extraction aliases.

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

AB122 Platform Study

Status: RECRUITING
Phase: PHASE1

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

Status: UNKNOWN
Phase: PHASE2

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Status: TERMINATED
Phase: PHASE2

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Status: COMPLETED
Phase: PHASE3

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Status: UNKNOWN
Phase: PHASE2/PHASE3

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

Status: RECRUITING
Phase: NA

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Status: RECRUITING
Phase: PHASE2

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

Status: RECRUITING
Phase: PHASE2

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC

Status: WITHDRAWN
Phase: PHASE2

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Status: RECRUITING
Phase: PHASE2

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Status: UNKNOWN
Phase: PHASE2

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Status: UNKNOWN
Phase: PHASE2